What type of study is this?

This is a In Vitro Study study.

September 12, 20250 citations

Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

NSNiccolò G. Santin NSNamrata SethiYale University SBStefania BelloneYale University

Puntos clave

The study found a significant increase in cytotoxicity of END(K)34 cells treated with Dato-DXd when cocultured with END(K)265 cells.
Coculture with END(K)265 led to an observed cytotoxicity increase of END(K)34 cells at a dose of 5 μg/mL, indicating effective targeting.
The bystander effect demonstrates that TROP2-targeted therapies could enhance treatment efficacy in poorly differentiated endometrial carcinomas.
Statistical analysis showed significant differences in cytotoxicity between treated cocultures and isolated END(K)34 cells, underscoring the potential of Dato-DXd.

Resumen

Bystander effect assay. Bystander killing effect was evaluated by admixing END(K)265 (3+ TROP2 expression) in vitro with carboxyfluorescein succinimidyl ester (CFSE)–stained END(K)34 cells (0 TROP2 expression). At dose 5 μg/mL, a significant increase in cytotoxicity of END(K)34 cells was seen when END(K)34 and END(K)265 were cultured together and treated with Dato-DXd when compared with ADC control–treated cocultures (P = 0.0167). In addition, a significant increase in cytotoxicity of END(K)34 cells was seen when the cocultures were treated with Dato-DXd as compared with isolated END(K)34 cells treated with Dato-DXd (P = 0.0329; *, P

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo